RxDoctor Payments Data

Manish Sheth, MD

Hematology & Oncology · Kettering, OHNPI 1205832730

Payments from drug & device makers

$28,810in general payments, 2019–2025

Across 479 payments — averaging $60.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$7K
  • AbbVie$5K
  • Incyte Corporation$3K
  • Novartis$2K
  • Johnson & Johnson$2K
  • Bayer$2K
  • plus $7K from 54 others

What the payments were for

  • Consulting fees$12,13351%
  • Travel & lodging$1,6937%
  • Food & beverage$9,40439%
  • Education$7073%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen27$7,446
AbbVie17$5,223
Incyte Corporation13$2,804
Novartis42$2,142
Johnson & Johnson(3 entities)21$1,912
Bayer19$1,874
Regeneron Healthcare Solutions, Inc.15$734
Pharmacyclics LLC, An Abbvie Company27$527
AstraZeneca17$490
E.r. Squibb & Sons, L.L.C.18$457
Pfizer34$421
Merck19$374
Genentech USA, Inc.22$330
Rigel Pharmaceuticals, Inc.7$320
Takeda Pharmaceuticals U.S.A., Inc.12$284
Eisai Inc.14$262
Gilead(2 entities)10$218
Daiichi Sankyo Inc.12$217
Seagen Inc.6$205
Lilly USA, LLC11$184
Beigene USA, Inc.5$174
Sanofi7$163
Bristol Myers Squibb10$150
ADC Therapeutics America, Inc.4$136
Ipsen Biopharmaceuticals, Inc8$127
Array Biopharma Inc7$115
Epizyme, Inc.6$113
Puma Biotechnology, Inc.7$111
Sobi, Inc1$84
Sirtex Medical Inc1$75
Morphosys, US Inc.3$72
Tersera Therapeutics LLC4$70
Caris MPI, Inc.1$68
AVEO Pharmaceuticals, Inc.3$67
Foundation Medicine, Inc.4$63
G1 Therapeutics, Inc.3$54
Deciphera Pharmaceuticals Inc.3$52
Alnylam Pharmaceuticals Inc.3$50
Genmab U.S., Inc.2$45
Adaptive Biotechnologies Corporation2$40
Kyowa Kirin, Inc.2$39
Blueprint Medicines Corporation2$37
CTI Biopharma Corp.2$34
Aurobindo Pharma USA, Inc.2$32
Clovis Oncology, Inc.2$31
Novocure Inc.1$28
Tesaro, Inc.1$27
Exelixis Inc.2$26
Boehringer Ingelheim2$24
Janssen Scientific Affairs, LLC1$24
Organon1$23
Aadi Bioscience, Inc.1$22
Servier Pharmaceuticals LLC1$21
Stemline Therapeutics Inc.1$21
Acceleron Pharma, Inc.1$20
Taiho Oncology, Inc.1$17
Agios Pharmaceuticals, Inc.1$16
Astellas Pharma US Inc1$15
Mylan Institutional Inc.1$15
Heron Therapeutics, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,810 in reported general payments places this provider in the 65th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio

Medicare billing

Part B allowed, 2024
$193,809
Medicare patients
553
Services billed
5,409

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide16$309,547
IbrancePalbociclib17$258,927
CalquenceAcalabrutinib Maleate17$205,353
VenclextaVenetoclax11$70,656
EliquisApixaban42$38,558
XareltoRivaroxaban11$11,411
Ondansetron Hcl70$2,917
Exemestane16$1,720
Hydroxyurea67$1,152
Oxycodone Hcl41$1,060
Anastrozole67$1,048
Dexamethasone38$1,027
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen37$987
Imatinib Mesylate13$970
Morphine Sulfate ErMorphine Sulfate14$711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$421$297,48459 claims
AstraZenecaCalquence$490$205,35317 claims
AbbVieVenclexta$5,223$70,65611 claims
Johnson & JohnsonXarelto$1,912$11,41111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 450 hematology & oncology providers in Ohio.

Other hematology & oncology in Kettering

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →